Clinical trials for Nutrition specialty
IACUC Protocol # G2016-132
Status: Currently enrolling
Cachexia, a loss of muscle, occurs in a variety of diseases, including congestive heart failure, cancer, and chronic kidney disease. Sarcopenia is the muscle loss that occurs with normal aging, in the absence of disease. This muscle loss affects strength, immune function, wound healing, and is associated with shorter survival. Because cachexia and sarcopenia are such common and serious problems, drugs are being developed for people and pets with this condition. One of the main challenges of studying the syndromes of cachexia and sarcopenia is the accurate assessment of the degree of muscle loss. When severe muscle loss is present, it is easy to identify (although still hard to measure) the exact amount of muscle lost. However, at this severe stage, treatments are is less likely to be successful. Therefore, earlier identification of cachexia is desirable, as is an easy way to measure the degree of muscle loss.
We developed an ultrasound method of measuring muscle, the Vertebral Epaxial Muscle Score (VEMS). This technique has been validated in dogs but in order to develop this ultrasound method for cats, the goal of the current study is to assess feasibility and validity of the VEMS in cats of varying sizes.
Cats of various ages, weights and sexes will be eligible. Cats should be in ideal body condition
Cats that do not tolerate the radiographs and ultrasound procedure without sedation will be excluded.
The cost of the all procedures involved in the study are covered.
For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: email@example.com